Exclusive: Practo In Talks To Raise $100 Mn In Pre-IPO Round

Why It Matters

The raise underscores growing investor confidence in profitable digital‑health platforms and provides Practo with the runway to scale before its public debut, shaping consolidation trends in the health‑tech sector.

Key Takeaways

• Pre‑IPO round targets $100‑125 million at $700 million valuation
• Global private equity firm leads, existing investors also participating
• Capital earmarked for geographic expansion and strategic acquisitions
• Practo achieved EBITDA profitability FY25, revenue ₹234 cr
• Over 2 lakh doctors in US, $75 M GMV run rate

Pulse Analysis

India’s health‑technology sector has entered a phase where late‑stage startups are attracting sizable pre‑IPO capital, and Practo’s latest fundraising illustrates that shift. Sources tell Inc42 the company is negotiating a $100‑125 million round that will combine equity and debt, led by an unnamed global private‑equity firm. The transaction values Practo at roughly $700 million post‑money, placing it among the few Indian health‑platforms to breach the half‑billion mark before going public. Such valuations reflect investors’ confidence in digital health’s scalability and the growing appetite for structured exit pathways.

Founded in 2008, Practo has evolved from a simple appointment‑booking app into a full‑stack health‑services platform. It now offers tele‑consultations, medicine delivery, diagnostic bookings, and practice‑management software for clinics and hospitals, while operating 40 co‑branded dermatology clinics. The firm turned EBITDA‑positive in FY25, reporting ₹15 crore EBITDA on ₹234 crore revenue, and boasts a network of over 2 lakh doctors in the United States with a $75 million GMV run rate. The fresh capital will fund geographic expansion, particularly in the UAE and US, and fuel strategic acquisitions to broaden its service suite.

The pre‑IPO raise positions Practo for a 2027 market debut, giving it a runway to solidify market share before the listing. For investors, the mix of equity and debt offers upside participation while mitigating dilution risk, a structure increasingly common in late‑stage Indian tech deals. Competitors such as 1mg and PharmEasy may feel pressure to accelerate their own financing or consolidation strategies. Overall, Practo’s fundraising underscores the maturation of India’s digital health ecosystem and signals that profitable, data‑rich platforms are becoming prime candidates for public markets.